These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25429378)

  • 1. Noninvasive characterization of graft steatosis after liver transplantation.
    Karlas T; Kollmeier J; Böhm S; Müller J; Kovacs P; Tröltzsch M; Weimann A; Bartels M; Rosendahl J; Mössner J; Berg T; Keim V; Wiegand J
    Scand J Gastroenterol; 2015 Feb; 50(2):224-32. PubMed ID: 25429378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.
    Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.
    Scheiner B; Mandorfer M; Schwabl P; Payer BA; Bucsics T; Bota S; Aichelburg MC; Grabmeier-Pfistershammer K; Stättermayer A; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
    PLoS One; 2015; 10(11):e0143429. PubMed ID: 26599080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?
    Machado CM; Leite NC; França PH; Cardoso CR; Salles GF; Villela-Nogueira CA
    Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):965-971. PubMed ID: 31377187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
    Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
    Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
    Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.
    Petta S; Grimaudo S; Cammà C; Cabibi D; Di Marco V; Licata G; Pipitone RM; Craxì A
    J Hepatol; 2012 Jun; 56(6):1356-62. PubMed ID: 22314430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
    J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases.
    Zhang RN; Zheng RD; Mi YQ; Zhou D; Shen F; Chen GY; Zhu CY; Pan Q; Fan JG
    Dig Dis Sci; 2016 Aug; 61(8):2284-2293. PubMed ID: 27059980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study.
    Trunečka P; Míková I; Dlouhá D; Hubáček JA; Honsová E; Kolesár L; Lánská V; Fraňková S; Šperl J; Jirsa M; Poledne R
    Dig Liver Dis; 2018 May; 50(5):490-495. PubMed ID: 29396131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
    Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
    World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
    Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
    Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
    Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
    Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver.
    Alam S; Islam MS; Islam S; Mustafa G; Saleh AA; Ahmad N
    Indian J Gastroenterol; 2017 Sep; 36(5):366-372. PubMed ID: 28975533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.